Cardiomyocyte death: Mechanisms and translational implications

Cell Death and Disease

Volumn 2, Issue 12, 2011, Pages

  Chiong, M ^a   Wang, Z V ^b   Pedrozo, Z ^a   Cao, D J ^b   Troncoso, R ^a   Ibacache, M ^a,b   Criollo, A ^c   Nemchenko, A ^c   Hill, J A ^c,d   Lavandero, S ^a,c  

^a UNIVERSITY OF CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Autophagy; Cardiovascular diseases; Heart; Necrosis

Indexed keywords

2 AMINOBENZAMIDE; 3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; BECLIN 1; CYCLOSPORIN A; DIPEPTIDE DERIVATIVE; DOXORUBICIN; FAS LIGAND; ISOXAZOLINE DERIVATIVE; METFORMIN; PIPERIDINE DERIVATIVE; PYRIDAZINONE DERIVATIVE; QUINOLINE DERIVATIVE; RAPAMYCIN; TETRAHYDROISOQUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; AUTOPHAGY; CARDIOVASCULAR DISEASE; CELL DEATH; DIABETES MELLITUS; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE ISCHEMIC REPERFUSION INJURY; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VIVO STUDY; MITOCHONDRION; MOLECULAR DYNAMICS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TRANSLATIONAL RESEARCH; TRANSLUMINAL CORONARY ANGIOPLASTY; CYTOLOGY; METABOLISM; NECROSIS; PATHOLOGY; PROTEIN SYNTHESIS; STEM CELL TRANSPLANTATION;

APOPTOSIS; AUTOPHAGY; CARDIOVASCULAR DISEASES; HUMANS; MITOCHONDRIA; MYOCYTES, CARDIAC; NECROSIS; PROTEIN BIOSYNTHESIS; STEM CELL TRANSPLANTATION;

EID: 84862908305     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.130     Document Type: Review

References (81)

1. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010; 72: 19-44.
2. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
3. Marambio P, Toro B, Sanhueza C, Troncoso R, Parra V, Verdejo H et al. Glucose deprivation causes oxidative stress and stimulates aggresome formation and autophagy in cultured cardiac myocytes. Biochim Biophys Acta 2010; 1802: 509-518.
4. Lipinski MM, Hoffman G, Ng A, Zhou W, Py BF, Hsu E et al. A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell 2010; 18: 1041-1052.
5. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007; 100: 914-922. (Pubitemid 46555697)
6. Yan L, Vatner DE, Kim SJ, Ge H, Masurekar M, Massover WH et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci USA 2005; 102: 13807-13812. (Pubitemid 41377660)
7. French CJ, Taatjes DJ, Sobel BE. Autophagy in myocardium of murine hearts subjected to ischemia followed by reperfusion. Histochem Cell Biol 2010; 134: 519-526.
8. Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, Kirshenbaum LA et al. Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. Cell Death Differ 2007; 14: 146-157. (Pubitemid 44911902)
9. Russell RR, 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495-503. (Pubitemid 39572099)
10. Hamacher-Brady A, Brady NR, Gottlieb RA. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 2006; 281: 29776-29787. (Pubitemid 44536987)
11. Gustafsson AB, Gottlieb RA. Autophagy in ischemic heart disease. Circ Res 2009; 104: 150-158.
12. Ma X, Foyil SR, Hill JA, Diwan A. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia-reperfusion injury. Unpublished Results 2011.
13. Buss SJ, Muenz S, Riffel JH, Malekar P, Hagenmueller M, Weiss CS et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2009; 54: 2435-2446.
14. McCormick J, Suleman N, Scarabelli TM, Knight RA, Latchman DS, Stephanou A. STAT1 deficiency in the heart protects against myocardial infarction by enhancing autophagy. J Cell Mol Med 2011; e-pub ahead of print 29 March 2011; doi: 10.1111/j. 1582-4934.2011.01323.x.
15. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2207-2215. (Pubitemid 38757586)
16. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003; 92: 715-724. (Pubitemid 36457635)
17. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA 2011; 108: 4123-4128.
18. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007; 117: 1782-1793. (Pubitemid 47036312)
19. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 2011; 123: 1073-1082.
20. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107: 1664-1670. (Pubitemid 36397337)
21. Zhang D, Contu R, Latronico MV, Zhang J, Rizzi R, Catalucci D et al. mTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest 2010; 120: 556-563.
22. Kushwaha SS, Raichlin E, Sheinin Y, Kremers WK, Chandrasekaran K, Brunn GJ et al. Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J 2008; 29: 2742-2750.
23. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007; 13: 619-624. (Pubitemid 46828485)
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
25. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol 2011; 301: H459-H468.
26. Bahro M, Pfeifer U. Short-term stimulation by propranolol and verapamil of cardiac cellular autophagy. J Mol Cell Cardiol 1987; 19: 1169-1178. (Pubitemid 18068091)
27. Pfeifer U, Fohr J, Wilhelm W, Dammrich J. Short-term inhibition of cardiac cellular autophagy by isoproterenol. J Mol Cell Cardiol 1987; 19: 1179-1184. (Pubitemid 18068092)
28. Weiss EP, Fontana L. Caloric restriction-powerful protection for the aging heart and vasculature. Am J Physiol 2011; 301: H1205-H1219.
29. Liao X, Wang X, Gu Y, Chen Q, Chen LY. Involvement of death receptor signaling in mechanical stretch-induced cardiomyocyte apoptosis. Life Sci 2005; 77: 160-174. (Pubitemid 40603501)
30. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-a. Circ Res 1997; 81: 627-635. (Pubitemid 27432751)
31. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis 2009; 14: 536-548.
32. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G et al. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 1999; 99: 3071-3078. (Pubitemid 29270439)
33. Potts MB, Vaughn AE, McDonough H, Patterson C, Deshmukh M. Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. J Cell Biol 2005; 171: 925-930. (Pubitemid 41815824)
34. Scheubel RJ, Bartling B, Simm A, Silber RE, Drogaris K, Darmer D et al. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival? J Am Coll Cardiol 2002; 39: 481-488. (Pubitemid 34117506)
35. Chua CC, Gao J, Ho YS, Xiong Y, Xu X, Chen Z et al. Overexpression of IAP-2 attenuates apoptosis and protects against myocardial ischemia/reperfusion injury in transgenic mice. Biochim Biophys Acta 2007; 1773: 577-583. (Pubitemid 46441511)
36. Bhuiyan MS, Fukunaga K. Inhibition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo. Eur J Pharmacol 2007; 557: 168-177. (Pubitemid 46186288)
37. Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 1999; 31: 1709-1715. (Pubitemid 29414590)
38. Bahi N, Zhang J, Llovera M, Ballester M, Comella JX, Sanchis D. Switch from caspase-dependent to caspase-independent death during heart development: essential role of endonuclease G in ischemia-induced DNA processing of differentiated cardiomyocytes. J Biol Chem 2006; 281: 22943-22952.
39. Bae S, Siu PM, Choudhury S, Ke Q, Choi JH, Koh YY et al. Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA. Am J Physiol 2010; 299: H1374-H1381.
40. Gustafsson AB, Tsai JG, Logue SE, Crow MT, Gottlieb RA. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J Biol Chem 2004; 279: 21233-21238. (Pubitemid 38656528)
41. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N et al. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 2000; 14: 729-739. (Pubitemid 30198571)
42. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001; 410: 549-554. (Pubitemid 32267191)
43. van Empel VP, Bertrand AT, van der Nagel R, Kostin S, Doevendans PA, Crijns HJ et al. Downregulation of apoptosis-inducing factor in harlequin mutant mice sensitizes the myocardium to oxidative stress-related cell death and pressure overload-induced decompensation. Circ Res 2005; 96: e92-e101.
44. Chen M, Zsengeller Z, Xiao CY, Szabo C. Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. Cardiovasc Res 2004; 63: 682-688. (Pubitemid 39078682)
45. Parra V, Verdejo H, Del CA, Pennanen C, Kuzmicic J, Iglewski M et al. The complex interplay between mitochondrial dynamics and cardiac metabolism. J Bioenerg Biomembr 2011; 43: 47-51.
46. Kuzmicic J, del Campo A, Lopez-Crisosto C, Morales PE, Pennanen C, Bravo-Sagua R et al. Mitochondrial dynamics: a potential new therapeutic target for heart failure. Rev Esp Cardiol 2011; 64: 916-923.
47. Parra V, Eisner V, Chiong M, Criollo A, Moraga F, Garcia A et al. Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc Res 2008; 77: 387-397. (Pubitemid 351197639)
48. Minamino T, Komuro I, Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res 2010; 107: 1071-1082.
49. Fu HY, Okada K, Liao Y, Tsukamoto O, Isomura T, Asai M et al. Ablation of C/EBP homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation 2010; 122: 361-369.
50. van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res 2005; 67: 21-29. (Pubitemid 40798289)
51. Mani K. Programmed cell death in cardiac myocytes: strategies to maximize post-ischemic salvage. Heart Fail Rev 2008; 13: 193-209.
52. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-1504. (Pubitemid 38063282)
53. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74: 86-107. (Pubitemid 26041012)
54. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79: 949-956. (Pubitemid 26359236)
55. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 2000; 102: 572-578. (Pubitemid 30639976)
56. Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol 2003; 284: H456-H463. (Pubitemid 36142871)
57. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000; 97: 5456-5461. (Pubitemid 30313740)
58. Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol 2001; 280: H2313-H2320.
59. Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y et al. Bax deficiency reduces infarct size and improves long-term function after myocardial infarction. Cell Biochem Biophys 2007; 47: 11-20.
60. Toth A, Jeffers JR, Nickson P, Min JY, Morgan JP, Zambetti GP et al. Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. Am J Physiol 2006; 291: H52-H60.
61. Balakumar P, Singh M. Anti-tumour necrosis factor-a therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 2006; 99: 391-397. (Pubitemid 44813905)
62. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-1047. (Pubitemid 32200174)
63. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602. (Pubitemid 38451714)
64. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF. Anti-tumor necrosis factor-a antibody limits heart failure in a transgenic model. Circulation 2001; 104: 1094-1097. (Pubitemid 32830389)
65. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140. (Pubitemid 36793081)
66. Bergman MR, Holycross BJ. Pharmacological modulation of myocardial tumor necrosis factor a production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996; 279: 247-254. (Pubitemid 27166918)
67. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002; 90: 1118-1122. (Pubitemid 35335602)
68. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008; 8: 207-220. (Pubitemid 351982539)
69. Henriquez M, Armisen R, Stutzin A, Quest AF. Cell death by necrosis, a regulated way to go. Curr Mol Med 2008; 8: 187-206. (Pubitemid 351982538)
70. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163. (Pubitemid 46209992)
71. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999; 85: 856-866. (Pubitemid 29504161)
72. 2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007; 117: 2431-2444. (Pubitemid 47494345)
73. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-662. (Pubitemid 40488559)
74. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-658. (Pubitemid 40488558)
75. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-481.
76. Lim SY, Davidson SM, Mocanu MM, Yellon DM, Smith CC. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther 2007; 21: 467-469. (Pubitemid 350231514)
77. Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases. Br Med Bull 2011; 98: 143-159.
78. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189-1200. (Pubitemid 351552018)
79. Laflamme MA, Murry CE. Heart regeneration. Nature 2011; 473: 326-335.
80. Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y et al. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol 2003; 284: H2351-H2359. (Pubitemid 36622451)
81. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-2512.